Celebrate the legacy of Hanson "Curly" Lilly, whose warmth, service, and dedication to helping others continue to inspire his ...

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...

Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...

Eli Lilly and Company (NYSE:LLY) is one of the 14 Best Aggressive Growth Stocks to Buy According to Analysts. On July 29, BMO ...

Now, Eli Lilly says its experimental GLP-1 pill is a success after the first phase-three trial. The company said more than 3,000 adults on the experimental oral medication lowered their weight by an ...

Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

It’s not clear just how many new jobs the investment will bring, though it is likely that a lot of the investment will be in automation.

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...